Sara Guerreiro

Mrs. Sara Guerreiro

Life and Health Sciences Research Institute, ICVS, Braga, Portugal
orcid
PhD student at ICVS, Medical School, University of Minho

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2019 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
CDChrysoula Dioli
Chrysoula Dioli
PPPatrícia Patrício
Patrícia Patrício
NSNuno Sousa
Nuno Sousa
Nikolaos KokrasNikolaos Kokras
Nikolaos Kokras
CDChristina Dalla
Christina Dalla
ISIoannis Sotiropoulos
Ioannis Sotiropoulos
Chronic stress, a suggested precipitant of brain pathologies, such as depression and Alzheimer’s disease, is known to impact on brain plasticity by causing neuronal remodeling as well as neurogenesis suppression in the adult hippocampus. Although many studies show that stressful conditions reduce the number of newborn neurons in the adult dentate gyrus (DG), little is known about whether and how stress impacts on dendritic development and structural maturation of these newborn neurons. We, herein, demonstrate that chronic stress impacts differentially on doublecortin (DCX)-positive immature neurons in distinct phases of maturation. Specifically, the density of the DCX-positive immature neurons whose dendritic tree reaches the inner molecular layer (IML) of DG is reduced in stressed animals, whereas their dendritic complexity is increased. On the contrary, no change on the density of DCX-positive neurons whose dendritic tree extends to the medial/outer molecular layer (M/OML) of the DG is found under stress conditions, whereas the dendritic complexity of these cells is diminished. In addition, DCX+ cells displayed a more complex and longer arbor in the dendritic compartments located in the granular cell layer of the DG under stress conditions; on the contrary, their dendritic segments localized into the M/OML were shorter and less complex. These findings suggest that the neuroplastic effects of chronic stress on dendritic maturation and complexity of DCX+ immature neurons vary based on the different maturation stage of DCX-positive cells and the different DG sublayer, highlighting the complex and dynamic stress-driven neuroplasticity of immature neurons in the adult hippocampus.

2 September 2022 in Molecular Psychiatry
Verified
Journal Article
Closed access
PDF file
Sara GuerreiroSara Guerreiro
Sara Guerreiro
MGMarco R. Guimarães
Marco R. Guimarães
JSJoana Silva
Joana Silva
CDChrysoula Dioli
Chrysoula Dioli
AVAnastasia Vamvaka-Iakovou
Anastasia Vamvaka-Iakovou
ISIoannis Sotiropoulos
Ioannis Sotiropoulos

7 February 2023 in Cells
Verified
Journal Article
Open access
PDF file
Sara GuerreiroSara Guerreiro
Sara Guerreiro
Patrícia MacielPatrícia Maciel
Patrícia Maciel
Neurodevelopmental disorders (NDDs) arise from the disruption of highly coordinated mechanisms underlying brain development, which results in impaired sensory, motor and/or cognitive functions. Although rodent models have offered very relevant insights to the field, the translation of findings to clinics, particularly regarding therapeutic approaches for these diseases, remains challenging. Part of the explanation for this failure may be the genetic differences—some targets not being conserved between species—and, most importantly, the differences in regulation of gene expression. This prompts the use of human-derived models to study NDDS. The generation of human induced pluripotent stem cells (hIPSCs) added a new suitable alternative to overcome species limitations, allowing for the study of human neuronal development while maintaining the genetic background of the donor patient. Several hIPSC models of NDDs already proved their worth by mimicking several pathological phenotypes found in humans. In this review, we highlight the utility of hIPSCs to pave new paths for NDD research and development of new therapeutic tools, summarize the challenges and advances of hIPSC-culture and neuronal differentiation protocols and discuss the best way to take advantage of these models, illustrating this with examples of success for some NDDs.

1 March 2024 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
SDSara Duarte-Silva
Sara Duarte-Silva
JSJorge Diogo Da Silva
Jorge Diogo Da Silva
DMDaniela Monteiro-Fernandes
Daniela Monteiro-Fernandes
MCMarta Costa
Marta Costa
ANAndreia Neves-Carvalho
Andreia Neves-Carvalho
Patrícia MacielPatrícia Maciel
Patrícia Maciel
Spinocerebellar ataxia type 3 (SCA3) is an adult-onset neurodegenerative disease caused by a polyglutamine expansion in the ataxin-3 (ATXN3) gene. No effective treatment is available for this disorder, other than symptom-directed approaches. Bile acids have shown therapeutic efficacy in neurodegenerative disease models. Here, we pinpointed tauroursodeoxycholic acid (TUDCA) as an efficient therapeutic, improving the motor and neuropathological phenotype of SCA3 nematode and mouse models. Surprisingly, transcriptomic and functional in vivo data showed that TUDCA acts in neuronal tissue through the glucocorticoid receptor (GR), but independently of its canonical receptor, the farnesoid X receptor (FXR). TUDCA was predicted to bind to the GR, in a similar fashion to corticosteroid molecules. GR levels were decreased in disease-affected brain regions, likely due to increased protein degradation as a consequence of ATXN3 dysfunction being restored by TUDCA treatment. Analysis of a SCA3 clinical cohort showed intriguing correlations between the peripheral expression of GR and the predicted age at disease onset in presymptomatic subjects and FKBP5 expression with disease progression, suggesting this pathway as a potential source of biomarkers for future study. We have established a novel in vivo mechanism for the neuroprotective effects of TUDCA in SCA3 and propose this readily available drug for clinical trials in SCA3 patients.

23 March 2025 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
DMDaniela Monteiro-Fernandes
Daniela Monteiro-Fernandes
ICIan Charles
Ian Charles
Sara GuerreiroSara Guerreiro
Sara Guerreiro
DCDaniela Cunha-Garcia
Daniela Cunha-Garcia
Joana Pereira-SousaJoana Pereira-Sousa
Joana Pereira-Sousa
Patrícia MacielPatrícia Maciel
Patrícia Maciel
Rett Syndrome (RTT) is a neurodevelopmental disorder caused by mutations in the X-linked gene encoding the methyl-CpG-binding protein 2 (MECP2). Impaired function of this transcriptional regulator leads to profound neurological defects, among which respiratory distress, motor function and cognitive disorders are prominent. Despite great advances in understanding RTT neurobiology, therapies that can meaningfully improve patients' symptoms are still needed. Here, we focused on 5-HT1A receptor-mediated serotonergic signaling as a potential therapeutical route for RTT. We report the effects of a drug candidate, NLX-101, a highly selective, biased agonist of 5-HT1A post-synaptic receptors at brainstem and cortical regions, on key phenotypes of RTT. Unrestrained whole-body plethysmography studies confirmed and extended the previous observation that single i.p. administration of NLX-101 dose-dependently reduced the occurrence and length of apneic events in Mecp2tm1.1Bird heterozygous female mice and largely corrected respiratory irregularity. Although no preservation of motor function was observed, early onset chronic administration of NLX-101 entirely prevented the cognitive deficits of the Mecp2tm1.1Bird mice both in the short and the long-term memory paradigms of the Novel Object Recognition upon 10 weeks of treatment, an effect that was maintained throughout animals' age. Similar effects were observed in the Fear Conditioning paradigm, with treated Rett mice performing as well as wild-type controls, highlighting the procognitive properties of NLX-101. This work provides compelling evidence of the therapeutic potential of targeting post-synaptic 5-HT1A receptors to improve cognitive function in patients with RTT while supporting its respiratory-rescue properties.

21 July 2025 in Journal of Neurochemistry
Verified
Journal Article
Open access
AAAlice Abbondanza
Alice Abbondanza
NKNawon Kim
Nawon Kim
RLRicardo A. S. Lima‐Filho
Ricardo A. S. Lima‐Filho
AAAzin Amin
Azin Amin
RARoberta G. Anversa
Roberta G. Anversa
TWTyler J. Wenzel
Tyler J. Wenzel
The field of Neurochemistry spent decades trying to understand how the brain works, from nano to macroscale and across diverse species. Technological advancements over the years allowed researchers to better visualize and understand the cellular processes underpinning central nervous system (CNS) function. This review provides an overview of how novel models, and tools have allowed Neurochemistry researchers to investigate new and exciting research questions. We discuss the merits and demerits of different in vivo models (e.g., Caenorhabditis elegans, Drosophila melanogaster, Ratus norvegicus, and Mus musculus) as well as in vitro models (e.g., primary cells, induced pluripotent stem cells, and immortalized cells) to study Neurochemical events. We also discuss how these models can be paired with cutting‐edge genetic manipulation (e.g., CRISPR‐Cas9 and engineered viral vectors) and imaging techniques, such as super‐resolution microscopy and new biosensors, to study cellular processes of the CNS. These technological advancements provide new insight into Neurochemical events in physiological and pathological contexts, paving the way for the development of new treatments (e.g., cell and gene therapies or small molecules) that aim to treat neurological disorders by reverting the CNS to its homeostatic state. image